Compare AbCellera Biologics Inc (ABCL) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Indonesia Energy Corporation Limited — how do they compare? AbCellera Biologics Inc trades at $9.77 (market cap $2.85B), while Indonesia Energy Corporation Limited trades at $2.94 (market cap $44.93M). The key difference: AbCellera Biologics Inc is far larger — about 63.4× Indonesia Energy Corporation Limited's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ABCL | INDO | |
|---|---|---|
Market Cap | $2.85B | $44.93M |
Sector | Health | Energy |
52-Week High | $9.34 | $6.74 |
52-Week Low | $2.78 | $2.49 |
Enterprise Value | $2.45B | $40.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
